Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. We are applying our expertise in the development of anti-infectives to advance a broad portfolio of antiviral and antibody-based therapies, each of which has the potential to significantly improve the standard of care. Our diverse pipeline addresses major viral and bacterial infections, including shingles, HCV, HIV and staph aureus infections.

Our goal is to build and develop a diverse portfolio of high-value anti-infective products. In addition to our strategy of in-licensing or acquiring novel antiviral compounds, we are leveraging partnerships with major pharmaceutical companies to develop products based on our MSCRAMM protein platform.